Promedior is a clinical-stage biotechnology company based in Malvern, PA, developing novel biologic therapeutics centered on Pentraxin-2 for the treatment of fibrosis. Its lead candidate, PRM-151 (recombinant human Pentraxin-2), recently completed a Phase 1b clinical study in idiopathic pulmonary fibrosis (IPF) and the data are under review. The company is advancing PRM-151 into additional indications, including myelofibrosis, a rare bone marrow disorder characterized by replacement of marrow with fibrous scar tissue. Promedior is also developing PRM-167, an rhPTX-2 variant optimized for intravitreal injection to target fibrovascular retinal diseases such as age-related macular degeneration, diabetic retinopathy and proliferative vitreoretinopathy. The company intends to use new capital to broaden and advance its Pentraxin-2 pipeline and to accelerate clinical development across these programs. Promedior is led by President and CEO Suzanne Bruhn, Ph.D. Promedior develops novel Pentraxin-2 biologic therapeutics that modulate monocyte-derived cells to reverse fibrotic and neovascular processes and promote normal healing. Its lead candidate, PRM-151 (recombinant human Pentraxin-2), is in a Phase 1b study in idiopathic pulmonary fibrosis (IPF) evaluating safety, tolerability and biomarker activity. The company plans to expand PRM-151’s clinical development into myelofibrosis with a Phase 2 study expected to begin near the end of 2012. Promedior is also advancing PRM-167, a rhPTX-2 variant for intravitreal injection, toward ophthalmic indications including AMD, diabetic retinopathy and PVR. The platform has shown activity in multiple validated models across lung, eye, kidney, heart and liver, and is positioned as a differentiated mechanism upstream of fibrosis and neovascularization. The recent financing strengthens the company’s ability to broaden and accelerate its Pentraxin-2 pipeline. Promedior is a clinical-stage biotechnology company focused on novel therapies to treat inflammatory and fibrotic diseases. Its lead drug candidate, PRM-151, is a recombinant human protein that promotes resolution of injury by regulating monocyte-derived cell populations involved in fibrosis, inflammation and autoimmunity. PRM-151 has shown preclinical efficacy in multiple validated models and demonstrated a strong safety profile. The company recently completed a Phase 1 clinical study of PRM-151. Promedior is developing PRM-151 for severe fibrotic and inflammatory conditions of the eye, lung and kidney. The company intends to expand the clinical development program for PRM-151 into Phase 2 in several indications.

Total raised

$37M

Funding rounds

3

Latest round

Series D

Latest activity

Oct 2012